by s2desi5_ksqtherapeutics | Nov 29, 2023 | Uncategorized
Phase 1/2 clinical study will evaluate the safety, pharmacokinetics, and preliminary efficacy of KSQ-001EX in melanoma, head and neck squamous cell carcinoma, and non-small cell lung cancer Lexington, Mass., November 29, 2023 — KSQ Therapeutics, Inc. (KSQ), a...
by s2desi5_ksqtherapeutics | Sep 6, 2023 | Uncategorized
Collaboration will provide full process development and manufacturing support for KSQ’s lead eTIL programs Lexington, Mass., September 6, 2023 — KSQ Therapeutics, Inc. (“KSQ”), a clinical-stage biotechnology company developing cancer therapies using its proprietary...
by s2desi5_ksqtherapeutics | Jul 23, 2023 | Uncategorized
Lexington, Mass., July 13, 2023 — KSQ Therapeutics, Inc. (“KSQ”), a clinical-stage biotechnology company developing cancer therapies using its proprietary CRISPRomics® discovery platform, announced today it has entered into a worldwide license and collaboration...
by s2desi5_ksqtherapeutics | May 17, 2023 | Uncategorized
Expanded collaboration focused on novel target discovery and validation to inform the development of targeted therapies that address resistance mechanisms in patients with cancer Agreement expands the companies’ successful ongoing collaboration focused on discovering...
